Ross Moat
Corporate Officer/Principal bij KINIKSA PHARMACEUTICALS, LTD.
Vermogen: 286 620 $ op 30-04-2024
Profiel
Ross Moat is currently the Chief Commercial Officer at Kiniksa Pharmaceuticals Ltd.
He previously worked as the General Manager at Synageva BioPharma Corp.
and as the VP-EMEA Marketing & Commercial Operations at Novartis Gene Therapies, Inc. Mr. Moat completed his undergraduate degree at Middlesex University.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 08-04-2024 | 16 276 ( 0.04% ) | 286 620 $ | 30-04-2024 |
Actieve functies van Ross Moat
| Bedrijven | Functie | Begin |
|---|---|---|
| KINIKSA PHARMACEUTICALS, LTD. | Corporate Officer/Principal | 01-02-2021 |
Eerdere bekende functies van Ross Moat
| Bedrijven | Functie | Einde |
|---|---|---|
| AVEXIS INC | Verkoop & Marketing | 01-06-2019 |
| SYNAGEVA BIOPHARMA CORP | Corporate Officer/Principal | - |
Opleiding van Ross Moat
| Middlesex University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| KINIKSA PHARMACEUTICALS, LTD. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Synageva BioPharma Corp.
 Synageva BioPharma Corp. BiotechnologyHealth Technology Synageva BioPharma Corp. is a biopharmaceutical company which focuses on the discovery, development, and commercialization of therapeutic products for patients with life-threatening rare diseases and high unmet medical need. The company is currently evaluating sebelipase alfa in global clinical trials for LAL Deficiency, a lysosomal storage disease associated with liver damage and accelerated atherosclerosis in children and adults, and in infants, premature death often before six months of age. Synageva BioPharma was founded in 1993 and is headquartered in Lexington, MA. | Health Technology |
Novartis Gene Therapies, Inc.
 Novartis Gene Therapies, Inc. BiotechnologyHealth Technology Novartis Gene Therapies, Inc. developed gene therapies for patients and families devastated by rare and life-threatening neurological genetic diseases. The firm’s robust AAV-based pipeline is used to provide advance treatments for Rett syndrome and Friedreich’s ataxia. The company was founded by John D. Harkey, Jr., David G. Genecov and John A. Carbona on March 8, 2010 and was headquartered in Bannockburn, IL. | Health Technology |